Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

Hansa Biopharma reports positive outcomes in five-year analysis of imlifidase.

Document Cited in Related
Vincent

NORDIC BUSINESS REPORT-October 17, 2023-Hansa Biopharma reports positive outcomes in five-year analysis of imlifidase

(C)2023 M2 COMMUNICATIONS http://www.m2.co.uk

Commercial-stage biopharmaceutical company Hansa Biopharma (Nasdaq Stockholm: HNSA) on Tuesday announced compelling results from a five-year extended pooled analysis of the 17-HMedIdeS-14 study.

Focused on desensitization in kidney transplant patients using imlifidase, the study demonstrates a remarkable 90% patient survival and 82% graft survival at the five-year mark. The patient survival rate aligns with the positive outcomes observed at the three-year post-transplant period. Notably, the mean estimated glomerular filtration rate (eGFR) at five years is 50 mL/min/m2, showcasing sustained positive outcomes. The study reinforces imlifidase as a promising strategy for highly sensitized patients with donor-specific anti-HLA antibodies.

Imlifidase, originating from Streptococcus pyogenes, acts as an antibody-cleaving enzyme, specifically targeting and inhibiting IgG antibodies. It is conditionally approved in Europe as Idefirix[R] for desensitization treatment in highly sensitized adult kidney transplant patients. The strategic...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT